Arcus Biosciences, Inc. (RCUS) Earnings Call Transcripts
Arcus Biosciences, Inc.'s Latest Earnings Call - June 9, 2026
In Q2 FY2026, Arcus Biosciences emphasized its focus on the development of Casdatifan, projecting it as a $5 billion to $10 billion opportunity. The company reported a strong cash position, funded into the second half of 2028. Management highlighted the differentiation of Casdatifan from competitors, particularly Belzutifan, and outlined a comprehensive development strategy across multiple lines of therapy. No specific revenue or earnings figures were provided, and there was no change in guidance.
Reported metrics
| Metric | Value |
|---|---|
| Cash Position | Funded into H2 2028 (inline) |
| Casdatifan Enrollment | Expected full enrollment by end of 2026 (inline) |
| QUEMLI Study Readout | Early 2027 (inline) |
| I&I Portfolio Progress | PK data later this year (inline) |
Guidance from management
Management did not provide specific financial guidance but emphasized a strong cash position and strategic focus on Casdatifan, with key data readouts expected in 2027 and 2028.
What management said
All right. Let's kick off our next session with me, Terry [Audio Gap] company. Welcome. Very exciting times this year. And before we go to the question, which I have a lot, I'm going to turn it to you guys for opening remarks. So Terry.
Yes. A lot going on in the company. There's a lot of readouts. Can you walk us through like the timing for some of these readouts, including the PDAC, what's going on in the I&I program? I know that you guys started that Phase III, the PEAK1 study was the status for that. So maybe just kind of give us a status on these programs and the timing for the readout?
What analysts pressed on
Analysts questioned the reliability of Casdatifan data due to the lack of control arms in studies and the potential for inflated results. Concerns were also raised about the competitive landscape and the need for clear differentiation from Belzutifan.
Main topics on the call
- Casdatifan Development Focus — Arcus is investing 80% of its resources in Casdatifan, viewing it as a $5 billion to $10 billion opportunity. Management stated, 'we have demonstrated unequivocally we have a better molecule than the one other molecule t...
- Pipeline Progress — The company is advancing its I&I portfolio, with an X2 antagonist entering human trials imminently and PK data expected later this year. Management noted, 'we have somewhat quietly built a very strong immunology and info...
- Clinical Trial Timelines — Arcus is on track to fully enroll the first registrational study for Casdatifan by year-end 2026, with data expected in early 2028. The QUEMLI study in pancreatic cancer is anticipated to read out in early 2027.
- Strategic Collaborations — Arcus announced a collaboration with BMS for a bispecific VEGF PD-L1 study, emphasizing strategic partnerships while retaining commercial rights to Casdatifan.
Read the full Arcus Biosciences, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (RCUS) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 48 calls on record spanning May 27, 2020 to September 15, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 48 Arcus Biosciences, Inc. earnings call transcripts on record, spanning May 27, 2020 to September 15, 2026. Based on this history, Arcus Biosciences, Inc. reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RCUS
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 48
- First call
- May 27, 2020
- Most recent
- September 15, 2026
- Reporting cadence
- quarterly